Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat-Reference-Cited by-同舟云学术

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

Published:2020-11-22 Issue:2 Volume:14 Page:487-491
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Hohmann Nicolas¹²,Bozorgmehr Farastuk³,Christopoulos Petros³,Mikus Gerd¹,Blank Antje¹,Burhenne Jürgen¹,Thomas Michael³,Haefeli Walter E.¹

Affiliation:

1. Department Clinical Pharmacology and Pharmacoepidemiology University Hospital Heidelberg Heidelberg Germany

2. Department of Medical Oncology National Center for Tumor Diseases Heidelberg Germany

3. Department of Thoracic Oncology German Center for Lung Research (DZL) Thorax Clinic at Heidelberg University Hospital Heidelberg Germany

Funder

Dietmar Hopp Stiftung

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12921

Reference20 articles.

1. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

2. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer

3. Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer

4. U.S. Food and Drug Administration.Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf(2011). Accessed July 9 2020.

5. Isolated central nervous system progression on Crizotinib

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coadministration of fluconazole to boost subtherapeutic sirolimus concentrations: A case report;Pharmacology Research & Perspectives;2024-04-18

2. Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study);European Journal of Cancer;2023-11

3. Pharmacokinetic Boosting of Kinase Inhibitors;Pharmaceutics;2023-04-05

4. Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs;ESMO Open;2023-02

5. Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial;Lung Cancer;2022-09